Previous 10 | Next 10 |
Primary Endpoint Met with Highly Statistically Significant Results Final Data Readout Expected in Second Quarter of 2022 YAVNE, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio...
MediWound Ltd. (MDWD) Q4 2021 Earnings Conference Call March 17, 2022 08:30 ET Company Participants Monique Kosse - Investor Relations Sharon Malka - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Kevin DeGeeter - Oppenheime...
MediWound press release (NASDAQ:MDWD): Q4 GAAP EPS of -$0.15 in-line. Revenue of $5.49M (-18.1% Y/Y) misses by $0.05M. For further details see: MediWound GAAP EPS of -$0.15 in-line, revenue of $5.49M misses by $0.05M
Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for EscharEx Phase 2 Clinical Trial, with Full Data Set Anticipated in Second Quarter 2022 Raised Gross Proceeds of $10 Million through Public Equity Offering Conferenc...
ACN,ALDX,AVDL,OTCQX:AYRWF,CMC,CSIQ,DBI,DG,DXLG,OTCQX:EDVMF,GIII,HUT,IMV,KIRK,LICY,LQDA,MDWD,OTCQX:NLCP,OTCPK:PNGAY,RDHL,SIG,SYBX,OTCPK:VEOEY,XNET,ZEPP For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open
MediWound (NASDAQ:MDWD) is scheduled to announce Q4 earnings results on Thursday, March 17th, before market open. The consensus EPS Estimate is -$0.15 (-150.0% Y/Y) and the consensus Revenue Estimate is $5.54M (-17.3% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisio...
YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that o...
YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the ...
Gainers: DBV Technologies (NASDAQ:DBVT) +16%. EyePoint Pharmaceuticals (NASDAQ:EYPT) +14%. Antares Pharma (NASDAQ:ATRS) +10%. Nuvalent (NASDAQ:NUVL) +8%. Aquestive Therapeutics (NASDAQ:AQST) +7%. Losers: NuCana (NASDAQ:NCNA) -54%. MediWound (NASDAQ:MDWD) -15%....
MediWound (NASDAQ:MDWD) plunged 17.9% premarket after pricing its underwritten public offering of 5.2M shares at a public offering price of $1.92/share. Gross proceeds are expected to be ~$10M. Underwriters granted 30-day option to purchase up to an additional 78...
News, Short Squeeze, Breakout and More Instantly...
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in ne...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...